CymaBay Therapeutics (NASDAQ:CBAY) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on CBAY. B. Riley reissued a “neutral” rating and issued a $32.50 price objective (up from $29.00) on shares of CymaBay Therapeutics in a research report on Tuesday, February 13th. Lifesci Capital cut CymaBay Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. Raymond James cut shares of CymaBay Therapeutics from an “outperform” rating to a “market perform” rating and set a $32.50 price target for the company. in a research report on Tuesday, February 13th. William Blair lowered shares of CymaBay Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, February 12th. Finally, BTIG Research reissued a “neutral” rating on shares of CymaBay Therapeutics in a research note on Tuesday, February 13th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.65.

CymaBay Therapeutics Price Performance

NASDAQ CBAY opened at $32.48 on Friday. The company has a 50 day simple moving average of $32.44 and a 200-day simple moving average of $25.75. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of -33.48 and a beta of 0.32. CymaBay Therapeutics has a 52-week low of $7.26 and a 52-week high of $32.50.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.04). The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.42 million. On average, analysts predict that CymaBay Therapeutics will post -1.38 EPS for the current year.

Insider Transactions at CymaBay Therapeutics

In related news, Director Janet Dorling sold 6,000 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $31.97, for a total value of $191,820.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.00% of the stock is owned by insiders.

Institutional Trading of CymaBay Therapeutics

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in CymaBay Therapeutics in the 3rd quarter valued at approximately $230,000. Raymond James & Associates raised its holdings in shares of CymaBay Therapeutics by 14.7% in the 3rd quarter. Raymond James & Associates now owns 39,515 shares of the biopharmaceutical company’s stock valued at $589,000 after purchasing an additional 5,050 shares during the period. Raymond James Financial Services Advisors Inc. lifted its stake in CymaBay Therapeutics by 3.5% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 101,329 shares of the biopharmaceutical company’s stock valued at $1,511,000 after purchasing an additional 3,434 shares during the last quarter. Emerald Advisers LLC bought a new position in CymaBay Therapeutics during the third quarter worth about $14,668,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in shares of CymaBay Therapeutics in the third quarter valued at approximately $12,073,000. 95.03% of the stock is currently owned by institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC).